Sales of Eli Lilly’s blockbuster weight-loss drug Mounjaro have soared in India, making it the top-selling brand in October, just six months after its launch in the world's most populous nation.

The drug registered sales of ₹ 100 crore in October, unseating the previous best-selling antibiotic Augmentin, which recorded sales of ₹ 80 crore during the month, according to data from intelligence platform Pharmarack on Friday. Since its launch late in March 2025, Mounjaro's total sales have reached ₹ 333 crore.

Augmentin, the London-headquartered GSK’s broad-range antibiotic, still retains its top position on a moving annual total (MAT) basis, with sales of ₹ 863 crore in twelve months to October 2025. MAT refers to the total sales recorded over the latest 12-month period.

This marks

See Full Page